No Data
Henan Taloph Pharmaceutical Stock (600222.SH): has repurchased a total of 1.04% of its shares.
Gelonghui reported on January 13 that Henan Taloph Pharmaceutical Stock (600222.SH) announced that as of January 13, 2025, the company has cumulatively repurchased 5,947,100 shares through centralized bidding trade, accounting for 1.04% of the company's total share capital, an increase of 0.22% compared to the last disclosed number. The highest price for the repurchased shares was 5.42 yuan/share, the lowest price was 3.82 yuan/share, and the total amount paid was 27,547,437.40 yuan (excluding trading fees).
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Henan Taloph Pharmaceutical Stock (600222.SH): Participating in the national Chinese Patent Medicine procurement alliance's centralized volume procurement is expected to be selected.
On January 2, Gelonghui reported that Henan Taloph Pharmaceutical Stock (600222.SH) announced its participation in the national centralized procurement bidding organized by the National Chinese Patent Medicine Joint Procurement Office (referred to as "Joint Procurement Office"). According to the announcement released by the Joint Procurement Office on December 30, 2024, regarding the planned selection results for the national centralized procurement alliance of Chinese Patent Medicine, the company's products, Shuanghuanglian Oral Liquid and Danshen Oral Liquid, are proposed to be selected for this centralized procurement.
Henan taloph pharmaceutical stock (600222.SH): The proportion of shares indirectly controlled by shanghai land increased to 8.71%.
On December 9, Gelonghui reported that Henan Taloph Pharmaceutical Stock (600222.SH) announced it had received a notice from shareholders Zhongsheng Industrial regarding changes in equity. During this period, its indirect shareholder Shanghai Landu Health Industry Investment Management Co., Ltd. (referred to as "Shanghai Landu") gained control of Zhongsheng Industrial's shareholders Gongyi City Zhulin Jinzhu Trading Co., Ltd. (referred to as "Jinzhu Trading") and Gongyi City Zhulin Litian Technology Development Co., Ltd. (referred to as "Litian Technology") due to an agreement, resulting in an increase in the proportion of shares indirectly controlled by Shanghai Landu in the company from 0% to 8.71%. This change in equity does not trigger a mandatory takeover offer and does not involve the company's control.
henan taloph pharmaceutical stock (600222.SH) plans to distribute 0.1 yuan per 10 shares in the first three quarters, with ex-rights and ex-dividends on December 9.
henan taloph pharmaceutical stock (600222.SH) announced that the company plans to distribute 1 share for every 10 shares to all shareholders in the first three quarters of 2024...
Solid Earnings May Not Tell The Whole Story For Henan Taloph Pharmaceutical StockLtd (SHSE:600222)
Why Investors Shouldn't Be Surprised By Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) 30% Share Price Plunge
